In vitro and in vivo chemo-phototherapy of magnetic TiO 2 drug delivery system formed by pH-sensitive coordination bond
Source abstract
Abstract
To achieve tumor-specific delivery of doxorubicin, TiO 2 @Fe 3 O 4 /PEI/delivery of doxorubicin conjugates were designed and synthesized. Fe 3 O 4 could act as magnetically responsive carriers and enhance the visible light photodynamic activities of TiO 2 . Delivery of doxorubicin was conjugated via coordination bond. The drug release rate at pH 5.2 was much faster than that at pH 7.4, due to pH-sensitive coordination bond. Besides, TiO 2 @Fe 3 O 4 /PEI/delivery of doxorubicin showed high antitumor efficacy combining with phototherapy, good bio-safety, higher cellular uptake with an external magnetic field, and less toxicity in vitro and in vivo. These results suggested that TiO 2 @Fe 3 O 4 /PEI/delivery of doxorubicin may be promising for high tumor treatment efficacy with minimal side effects in future.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Graphene and Nanomaterials Applications · Nanoparticle-Based Drug Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, China
Collaborative Innovation Center of New Drug Research and Safety Evaluation, Zhengzhou, China
References (33)
Show source-provided references
1. 10.1007/s10565-006-0139-410.1007/s10565-006-0139-4 ↗
2. 10.1016/j.freeradbiomed.2005.03.02910.1016/j.freeradbiomed.2005.03.029 ↗
3. 10.1016/j.actbio.2013.10.03710.1016/j.actbio.2013.10.037 ↗
4. 10.1016/j.jconrel.2012.08.02010.1016/j.jconrel.2012.08.020 ↗
5. 10.1016/j.biomaterials.2011.08.01410.1016/j.biomaterials.2011.08.014 ↗
6. 10.1016/S0928-0987(03)00164-710.1016/S0928-0987(03)00164-7 ↗
7. Nishiyama N · Cancer Res · 2003 · 63 · 8977
8. 10.1002/anie.20070521110.1002/anie.200705211 ↗
9. 10.1038/nmat304210.1038/nmat3042 ↗
10. 10.1016/j.ijpharm.2006.03.05210.1016/j.ijpharm.2006.03.052 ↗
11. 10.1021/ja810011p10.1021/ja810011p ↗
12. 10.1016/j.ijpharm.2012.07.05910.1016/j.ijpharm.2012.07.059 ↗
13. 10.1021/jp806751k10.1021/jp806751k ↗
14. 10.3109/17435390.2011.63407910.3109/17435390.2011.634079 ↗
15. 10.1016/j.carbon.2011.10.00210.1016/j.carbon.2011.10.002 ↗
16. 10.1002/smll.20060048810.1002/smll.200600488 ↗
17. 10.1016/j.bej.2006.09.00810.1016/j.bej.2006.09.008 ↗
18. 10.1016/j.colsurfb.2013.09.05710.1016/j.colsurfb.2013.09.057 ↗
19. 10.1021/jp045989g10.1021/jp045989g ↗
20. 10.3109/02652048.2015.106591810.3109/02652048.2015.1065918 ↗
21. 10.1016/j.jconrel.2010.09.01210.1016/j.jconrel.2010.09.012 ↗
22. 10.1016/S0168-3659(01)00281-410.1016/S0168-3659(01)00281-4 ↗
23. 10.1016/j.biomaterials.2010.09.07710.1016/j.biomaterials.2010.09.077 ↗
24. 10.1016/j.biomaterials.2012.09.03910.1016/j.biomaterials.2012.09.039 ↗
25. 10.1016/j.seppur.2015.05.01910.1016/j.seppur.2015.05.019 ↗
26. 10.1016/j.cap.2013.03.02210.1016/j.cap.2013.03.022 ↗
27. Yang XL · Sci Rep-Uk · 2015 · 5 · 1
28. 10.1016/j.apsusc.2014.02.00610.1016/j.apsusc.2014.02.006 ↗
29. 10.1021/ie051098z10.1021/ie051098z ↗
30. 10.1016/j.jphotobiol.2014.01.01710.1016/j.jphotobiol.2014.01.017 ↗
31. 10.1007/s10529-014-1708-x10.1007/s10529-014-1708-x ↗
32. 10.1080/00914037.2015.105563210.1080/00914037.2015.1055632 ↗
33. 10.1021/la301099q10.1021/la301099q ↗